Characterization of acute renal failure due to cisplatin in cancer patients
DOI:
https://doi.org/10.56294/shp2025282Keywords:
Acute kidney failure, cisplatin, cancerAbstract
Introduction. Cisplatin is the most nephrotoxic antineoplastic drug and the main cause of acute renal failure in cancer patients. Aim. To characterize acute renal failure due to cisplatin in oncology patients treated in the Nephrology clinic belonging to the “III Congreso” Hospital in the period 2020-2022. Method. An observational, descriptive and cross-sectional study was carried out in oncological patients with acute renal failure due to cisplatin, belonging to the Nephrology clinic of Hospital III Congreso, Pinar del Río city, during the period 2020-2022. Variables were defined as: sex, age, presence of active oncological disease, presence of acute renal failure, stage of acute renal failure, urinary volume, urinary sediment, risk factors. The universe was made up of 52 patients, taking as a sample 23 who met the inclusion criteria. The collection of information took into account theoretical, empirical and statistical methods. Results. Male patients aged ≥ 60 years predominated. There was a higher frequency of active neoplastic disease in relation to ARF. Patients who presented ARF predominated for 52.17% and in Stage II of the disease, with a urinary volume of 0.5-3 L/24 hours. Active urinary sediment predominated for 52.17%. Hypovolemia was the risk factor most associated with ARF, for 39.13%. Conclusions. Acute kidney damage, both functional and structural, should be studied more precisely in a cancer patient subjected to toxic drug attacks, in order to prevent kidney consequences.
References
1. Heras Benito M, Calle García L, Fernández-Reyes L M. Carta al Director A propósito de la onconefrología: enfermedad renal crónica en pacientes oncológicos no hospitalizados. Nefrología [Internet] 2020 [citado 26 Jul 2021]; 40(3):[aprox. 14 p.] 365-6. Available from: https://www.revistanefrologia.com/es-a-proposito-onconefrologia-enfermedad-renal-articulo-S0211699519301134.
2. Alonso F, Auñón P, Cavero T, Salgueira M, Praga M, Quiroga B, et al. Consulta monográfica de onconefrología. Justificación y puesta en marcha. Nefrología [Internet] 2021 [citado 26 Jul 2021]; 41(2):[aprox. 11 p.] 154-164. Available from: https://www.revistanefrologia.com/en-pdf-S0211699520301715.
3. Finkel KW. Onconefrología:enfermedad renal en pacientes con cáncer. En Schorecki K, Chertow Glenn M, Marsden Philip A, Taal Maarten W, Yu Alan SL, editores. Brenner y Rector. El riñón. Vol 2.10 ed.España:Elsevier;2018.p.1390-1407
4. Izzedine H, Perazella M. Onco-nephrology: An appraisal of the cancer and chronic kidney disease links. Nephrol Dial Transplant [Internet] 2015 [citado 26 Jul 2021]; 30 (12):[aprox. 11 p.]1979-88. Available from: file:///C:/Users/laptop/AppData/Local/Temp/ONCKDlink.pdf
5. Li Y, Chen X, Wang Y, Hu J, Xu J, Jiang W, et al. Epidemiology of acute kidney injury and associated factors among patients with malignancy: Analysis of hospital inpatient database in Shanghai, China. J Onco-Nephr [Internet] 2019 [citado 26 Jul 2021]; 3(1):[aprox. 10 p.]. Available from: https://journals.sagepub.com/doi/pdf/10.1177/2399369319830096
6. Wong G, Staplin N, Emberson J, Baigent C, Turner R, Chalmers J, et al. Chronic kidney disease and the risk of cancer: An individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer [Internet] 2016 [citado 26 Jul 2021]; 16:[aprox. 12 p.]. Available from:https://www.researchgate.net/publication/305376961_Chronic_kidney_disease_and_the_risk_of_cancer_An_individual_patient_data_metanalysis_of_32057_participants_from_six_prospective_studies/link/5fc2127f458515b7977cb318/download.
7. Ministerio de Salud Pública. Anuario Estadístico de Salud 2019. 48 edición. La Habana; 2020. Disponible en: http://bvscuba.sld.cu/anuario-estadistico-decuba /
8. Díaz-Mederos, E., Peñate-Tamayo, F. D., et al. Consulta monográfica de Onconefrología, experiencia en Villa Clara. Nefrología [Internet] 2021 [citado 26 Jul 2021];. Available from: https://oncocienfuegos2021.sld.cu/index.php/oncocfg/conferencias/paper/veiew/218/0
9. Conde Sánchez L. Registró Cuba en 2020 un incremento en las personas mayores de 60 años. Granma 2021 Ene 29. Citado 15 julio 2021.
10. Lorenzo V, López Gómez J. Enfermedad Renal Crónica. Nefrología al día [Internet] 2021 [citado 26 Jul 2021]. Available from: https://www.nefrologiaaldia.org/es-pdf-enfermedad-renal-cronica-136.
11. Cosmai L, Porta C, Gallieni M, Perazella M. Onco-nephrology: A decalogue. Nephrol Dial Transplant [Internet] 2016[ citado 26 Jul 2021]; 31(4):[aprox. 10 p.] 519-9. Available from: https://air.unimi.it/retrieve/handle/2434/314897/780048/Gallieni_Onco_2016.pdf
12. Capasso A, Benigni A, Capitanio U, Danesh F, Di Marzo V, Gesualdo L, et al. Summary of the International Conference on Onco-Nephrology: An emerging field in medicine. Kidney International. [Internet] 2019 [citado 26 Jul 2021];96(3):[aprox. 25 p.] 555-67. Available from: https://air.unimi.it/retrieve/handle/2434/674370/1382088/Capasso%20_Summary%20of%20the%20International%20Conference%20on%20Onconephrology%20KI.pdf
13. Cosmai L, Porta C, Perazella M, Launay-Vacher V, Rosner M, Jhaveri K, et al. Opening an onconephrology clinic: Recommendations and basic requirements. Nephrol Dial Trasp .[Internet] 2018[ citado 26 Jul 2021]; 33(9):[aprox. 8 p.] 1503-10. Available from: https://academic.oup.com/ndt/article/33/9/1503/5049712
14. Arjona-Barrionuevo J, Gonzales Vargas-Machuca M, Guerrero-Márquez F, Gil-Sacaluga L, Gentil-Govantes MA. Utility of a cardiorenal monographic consultation to reduce the cardiovascular mortality of the renal transplant patient. J Cardiol Cardiovasc Sci [Internet] 2019 [citado 26 Jul 2021]; 3(3):[aprox 8 p.]. Available from: https://www.cardiologyresearchjournal.com/articles/utility-of-a-cardiorenal-monographic-consultation-to-reduce-the-cardiovascular-mortality-of-the-renal-transplant-patient.pdf
15. Herrera Valdés R. Enfermedad renal crónica: enfoque sistemico, epidemiológico, clínico e intersectorial. En: Quesada Pantoja J, editor. Nefrología. La Habana: Editorial Ciencias Médicas 2016. p. 102-30.
16. De Francisco A, Macia M, Alonso F, García P, Gutierrez E, Quintana L, et al. Onconefrología: Conexión cáncer y riñón 2019:[aprox. 13 p.]. Disponible en nefrologia-dia-202.pdf
17. Soukup T, Lamb B, Arora S, Darzi A, Sevdalis N, Green J. Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: An overview and synthesis of the available literature. J Multidiscip Healthc [Internet] 2018 [citado 26 Jul 2021]; 11:[aprox. 13 p.] 49-61. Available from: file:///C:/Users/laptop/AppData/Local/Temp/Successful_strategies_in_implementing_a_multidisci.pdf
18. Sociedad Española de Nefrología.[Internet]. Grupo Español de Onconefrología (ONCONEFRO). 2018 [citado 12 Ago 2021]. [aprox. 3 pantallas]. Disponible en: https://www.senefro.org/modules.php?name=grupos&d op=viewgroup&idgroup=14245.
19. Rosner M, Perazella M. Acute kidney injury in patients with cancer. N Engl J Med [Internet] 2017 [citado Jul 2021]; [aprox. 14 p.]. Available from: https://www.researchgate.net/publication/326878570_Acute_Kidney_Injury_in_Patients_With_Cancer/link/5d24ce42a6fdcc2462d0517a/download
20. Izzedine H, Perazella M. Anticancer drug-induced acute kidney injury. Kidney Int Rep [Internet] 2017[ citado 26 Jul 2021];[aprox. 28 p.]. Available from: https://www.researchgate.net/publication/313815100_Anticancer_Drug-Induced_Acute_Kidney_Injury
21. Arias M, Moreso F. Proyecto Prometeo 2016: Cáncer en el trasplantado renal: ¿se puede prevenir? Nefrologia [Internet] 2018 [citado 26 Jul 2021]; 9(S1) [aprox. 28 p.]. Available from: https://www.revistanefrologia.com/es-pdf-X2013757518622216
22. Cheung C, Tang S. An update on cancer after kidney transplantation. Nephrol Dial Transplant [Internet] 2019 [citado Jul 2021]; 34:[aprox. 7 p.]. Available from: https://academic.oup.com/ndt/article/34/6/914/5107809
23. Pérez-Sánchez L, Gines Casanova A, Morales A. Biomarcadores de nefrotoxicidad capaces de identificar pacientes oncológicos en riesgo de desarrollar daño renal. Farma Journal [Internet] 2019 [citado 26 Jul 2021]; 4(2):[aprox. 9 p.]. Available from: https://revistas.usal.es/index.php/2445-1355/article/view/fj2019424150.
24. Perazella MA, Izzadine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015; 87:909-17.
25. De Francisco A, Arias Guillén M, Pérez-Valderrama B, C S. Post-contrast acute kidney injury in cancer patients. Nefrología [Internet] 2019 [ citado 26 Jul 2021];39 [aprox. 8 p.]. Available from: https://www.revistanefrologia.com/en-pdf-S2013251419301610
26. Cosmai L, Porta C, Foramitti M, Perrone V, Mollica L, Gallieni M, et al. Preventive strategies for acute kidney injury in cancer patients. CKJ [Internet] 2021 [citado 10 Ago 2021]; 14(1):[aprox. 14 p.]. Available from: doi: 10.1093/ckj/sfaa127
27. Malyszko J, Bamias A, Danesh F, Debska-Slizien A, Gallieni M, Gertz M, et al. Conferencia de Controversias de KDIGO sobre Onconefrología: enfermedad renal en procesos hematológicos malignos y aumento de cáncer después del trasplante de riñón. Nefrología al día [Internet] 2020 [citado 26 Jul 2021]:[aprox. 22 p.]. Available from: https://static.elsevier.es/nefro/monografias/1/369/369_180320212108.pdf.
28. Torres da Costa e Silva V, Costalonga E, Coelho F, Caires R, Burdmann E. Assessment of kidney function in patients with cancer. Adv Chronic Kidney Dis [Internet] 2018[ citado 26 Jul 2021]; 25(1):[aprox. 8 p.]. Available from: https://www.ackdjournal.org/action/showPdf?pii=S1548-5595%2817%2930187-8
29. De Francisco A. Efectos renales adversos del tratamiento del cáncer. NefroPlus.2019;11(1):1-16.
30. Sprangers B, Abudayyeh A, Latcha S, Perazella M, Jhaveri K. How to determine kidney function in cancer patients? Eur J Cancer [Internet] 2020[ citado 26 Jul 2021]; 132:[aprox. 8 p.]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0959804920301763
31. Chancharoenthana W, Wattanatorn S, Vadcharavivad S, Eiam-Ong S, Leelahavanichkul A. Agreement and precision analyses of various estimated glomerular filtration rate formulae in cancer patients. Sci Rep [Internet] 2019 [citado 26 Jul 2021]; 9:[aprox. 11 p.]. Available from: https://www.researchgate.net/publication/338020226_Agreement_and_Precision_Analyses_of_Various_Estimated_Glomerular_Filtration_Rate_Formulae_in_Cancer_Patients/link/5fb66caa458515b7975127e2/download
32. Ballová V, Provencio Pulla M. ESMO HANDBOOK of cancer treatments in special clinic situations 2013.Available from: http://mauriciolema.webhost4life.com/rolmm/downloads/files/ESMOCaRxInSpecClinSit2013.pdf
33. De Francisco A, Macía M, Alonso F, García P, Gutiérrez E, Quintana L, et al. Onco-Nefrología: cáncer, quimioterapia y riñón. Nefrología [Internet] 2019 [citado 26 Jul 2021]; 39(5):[aprox. 9 p.]. Available from: https://www.revistanefrologia.com/es-pdf-S021169951930027X.
34. Thavarajah S, Choi M. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach. Am J Kidney Dis [Internet] 2019 [citado 26 Jul 2021]; 74(5):[aprox. 7 p.]. Available from: https://www.ajkd.org/article/S0272-6386(19)30767-X/pdf
35. Escobar Álvarez Y, de las Peñas Bataller R, Perez Altozano J, Ros Martínez S, Sabino Álvarez A, Blasco Cordellat A, et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). ClinTransl Oncol [Internet] 2021[ citado 5 Ago 2021]:[aprox. 9 p.]. Available from: https://doi.org/10.1007/s12094-021-02580-2.
36. Z.I. Cherney D, S. Rosenson R, R. Lawler P. Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease. J Am Coll Cardiol [Internet] 2019 [citado 26 Jul 2021]; 73(23):[aprox. 4 p.]. Available from: http://www.onlinejacc.org/content/73/23/2971.
37. López Gómez J, Vega Martínez A. Alteraciones Cardiovasculares en la Enfermedad Renal Crónica. Nefrología al día [Internet] 2020[ citado 26 Jul 2021]:[aprox. 16 p.]. Available from: https://www.nefrologiaaldia.org/es-pdf-alteraciones-cardiovasculares-enfermedad-renal-cronica-179.
38. Rodrigo Orozco B. Enfermedad cardiovascular (ECV) En la enfermedad renal Crónica (ERC). Rev. méd.Clín.Las Condes[Internet] 2015 [citado 26 Jul 2021]; 26(2):[aprox. 13 p.]. Available from: https://www.elsevier.es/es-revista-revista-medica-clinica-las-condes-202-pdf-S0716864015000358.
39. Mendoza-Torres E, Bravo-Sagua R, Villa M, Flores N, José Olivares M, Calle X, et al. Enfermedades cardiovasculares y cáncer: ¿dos entidades mutuamente relacionadas? . Rev Chil Cardiol [Internet] 2019 [citado 26 Jul 2021]; 38:[aprox. 10 p.]. Available from: https://scielo.conicyt.cl/pdf/rchcardiol/v38n1/0718-8560-rchcardiol-38-01-00054.pdf.
40. Sociedad Argentina de Cardiología . Consenso de Cardio-Oncología. Rev. argent.cardiol [Internet]2019 [citado 26 Jul 2021]; 87(5):[aprox. 93 p.]. Available from: https://www.sac.org.ar/wp-content/uploads/2019/12/consenso-87-5.pdf
Published
Issue
Section
License
Copyright (c) 2025 Victor Manuel Hernández Valdés, Maydelis Cruza Lorenzo, Yangel Fuentes Milián, Yusleny Sánchez Horta (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
